Description
VT-464, also called as Seviteronel, is an oral, non-steroidal, lyase-selective CYP17 inhibitor to reach Phase II clinical trials in Breast cancer in USA (PO).
in vitro: Approximately 10-fold more selective towards lyase than hydroxylase. Selective inhibit